Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2021-09-23 Board/Management Inform…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
BOARD COMMITTEE CHANGE
Board/Management Information Classification · 100% confidence The document is a Form 6-K filing with the SEC, which is used by foreign issuers to report material information. The content specifically announces a change in the Board Committee membership, namely the appointment of Diana Layfield to the Science Committee effective October 1, 2021. There is no financial data, earnings information, or detailed report content. The document is short (2613 characters) and focuses solely on management/board changes. Therefore, it fits the category of Board/Management Information (MANG).
2021-09-23 English
NEW SUSTAINABILITY COMMITTEE OF THE BOARD
Board/Management Information Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting the establishment of a new Sustainability Committee of the Board. It is a regulatory announcement about a governance change, specifically the creation of a new board committee focused on sustainability. The document does not contain financial statements, earnings data, or detailed management discussion. It is not an annual or interim report, nor an earnings release. It is also not a proxy statement or voting results. The content fits best under Board/Management Information (MANG) as it announces a change in the company's board committee structure and governance related to sustainability oversight. The document length is 3701 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the classification is MANG with high confidence.
2021-09-23 English
New Sustainability Committee of the Board
Environmental & Social Information Classification · 95% confidence The document is an RNS announcement from AstraZeneca regarding the establishment of a new Sustainability Committee of the Board. It details the committee's purpose, members, and effective date. While it touches on sustainability, it is not an ESG report (SR) but rather a corporate governance announcement regarding board structure and committee formation. Given the specific nature of board committee changes, it fits best under Governance Information (CGR).
2021-09-23 English
Board Committee Change
Board/Management Information Classification · 99% confidence The document is a short announcement identified by the 'RNS Number' header and the closing statement referencing 'RNS, the news service of the London Stock Exchange'. The content announces a specific change: the appointment of a new member to the Science Committee (Diana Layfield). This type of announcement regarding changes in board or management structure fits the definition of 'Board/Management Information' (MANG). Although it is distributed via RNS, the specific nature of the content (a committee appointment) is more precise than the general 'RNS' fallback.
2021-09-23 English
ASTRAZENECA $360M IRISH MANUFACTURING INVESTMENT
Capital/Financing Update Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content focuses on announcing a $360 million investment in a new manufacturing facility in Ireland. It is a regulatory announcement about a capital investment but does not contain financial statements or detailed financial results. The document is about a significant investment project, which aligns with capital or financing updates. It is not an earnings release, annual report, or other financial report. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is 5327 characters, which is sufficient to contain substantive information about the investment rather than just a brief announcement or report publication notice.
2021-09-21 English
AstraZeneca $360m Irish manufacturing investment
Environmental & Social Information Classification · 99% confidence The document is clearly identified as an 'RNS Number' announcement from AstraZeneca PLC, dated September 21, 2021. The content describes a significant business investment ($360m facility in Ireland) and includes quotes from the CEO and Taoiseach. This type of announcement, distributed via the RNS service (which is explicitly mentioned at the end, stating RNS is approved by the FCA to act as a Primary Information Provider), is a general regulatory announcement that does not fit the specific categories like 10-K, ER, or CAP. Since it is a broad, material, non-financial-specific announcement distributed through the official regulatory news service, the most appropriate classification is the general regulatory filing category.
2021-09-21 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.